SVRA
Savara Inc.stockNASDAQ
Market OpenNov 19, 2026 3:00:20 PM EST
5.22USD+10.593%(+0.50)10,035,243
Pre-marketNov 19, 2026 9:29:30 AM EST
4.82USD+2.119%(+0.10)
Loading…
Loading…
1.15B
Healthcare
Biotechnology
CEO
Robert Neville
HQ
Austin, TX, USA
Previous Close
$4.72
Beta
1.39
52-Week High
$7.01 2025-12-12
52-Week Low
$4.13 2026-10-23
SMA 50
$4.88
SMA 200
$5.32
Avg. Vol 10D
3.82M
Avg. Vol 30D
2.90M
Avg. Vol 90D
2.18M
Relative Vol
3.42
220.62M
110.58M
50.12%
32,273,605
31.34%
12.94
54%/46%
73.56%
61.64%
0.4100%
600,000
204
55,394
207,972
Apr 26, 2010 · 1-for-25 (reverse)
-152.7M
-0.61
-130.9M
-151.05
Nov 18, 2026
Nov 16, 2026
Nov 15, 2026
Savara investors brace for earnings ahead of key FDA ruling ·
Investing.com
Nov 12, 2026
SVRA Profile
savara pharmaceuticals is an emerging specialty pharmaceutical company developing innovative pulmonary drugs for the treatment of serious and life-threatening conditions. the company's lead product, aerovanc is the first dry powder inhaled antibiotic for the treatment of methicillin-resistant staphylococcus aureus (mrsa) infection in patients with cystic fibrosis (cf). for more information, please see savara's website at www.savarapharma.com or www.aerovanc.com
SVRA Performance
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 4.72 | 2026-11-12 | +10.70% | 3.606 |
| 1M | 4.63 | 2026-10-19 | +12.85% | 1.791 |
| 3M | 5.58 | 2026-08-19 | -6.36% | 1.543 |
| 6M | 4.72 | 2026-05-19 | +10.70% | 1.204 |
| 1Y | 4.60 | 2025-11-19 | +13.59% | 1.388 |
| 2Y | 2.94 | 2024-11-19 | +77.72% | — |
| 5Y | 1.08 | 2021-11-19 | +383.80% | 0.912 |
SVRA Stock Summary
Savara Inc. (NASDAQ:SVRA) stock price today is $5.23, and today's volume is 9,895,528. SVRA is up 10.699% today. The 30 day average volume is 2.90M. SVRA market cap is $1.15B with 220.62M shares outstanding.
